Nivolumab vs Pembrolizumab
Nivolumab vs Pembrolizumab: Overview
This comparison examines the pharmacological differences between Nivolumab and Pembrolizumab.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Nivolumab — 27 days; Pembrolizumab — 26 days.
Chemical Properties
Type: Nivolumab — Antibody; Pembrolizumab — Antibody.